Consecutively, the T-cell comes close to and recognises the myeloma cell. These have shown promising results in heavily pre-treated patients. Expert opinion Antibody therapy has significantly enhanced the armamentarium against MM. Further research should focus on tailoring the combination regimens based ...
The overall response rate for patients getting teclistamab-cqyv was over 60%. Antibody-drug conjugates are called "off-the-shelf" treatments. They're not made specifically for you, like CAR T-cell therapy. Anyone can take them, which makes them easier for cancer centers to use. What Are ...
In the study, 143 patients with no prior T-cell reintroduction therapy received 0.4 mg/kg weekly, which was analyzed for an overall response rate (ORR) of 74.1 percent (95 percent CI, 66.1-81.1 percent) and a strict complete remission (sCR) rate of 24 percent. Complete remission (CR) an...
Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma Forty patients with plasma cell dyscrasias underwent high-dose chemoradiotherapy and either anti-B-cell monoclonal antibody (MoAb)-treated autologous, anti... KC Anderson,J Andersen,R Soiffer,... - 《Leukemia & Lymphoma...
Monoclonal antibody therapy has emerged as a viable treatment option for patients with lymphoma and some leukemias. It is now beginning to be investigated ... DG Maloney,K Donovan,TJ Hamblin - 《Seminars in Hematology》 被引...
“This is the second Phase 3 trial to demonstrate superior results with Sarclisa combination therapy over a standard of care regimen, adding to the growing body of evidence that our anti-CD38 monoclonal antibody has the potential to make a meaningful difference for patients,” said ...
Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis. PMID: 33387628 Daratumumab for treatment-refractory antibody-mediated diseases in neurology. PMID: 35098616 Daratumumab subcutaneous formulation for the treatment of multiple myeloma. PMID: 32750265 ...
respectively) [24,25]. As a result of the SIRIUS trial, with findings in concordance with those of GEN501, the FDA approved daratumumab on November 16, 2015, for the treatment of refractory myeloma in patients who have received at least three previous lines of therapy, including a PI and ...
摘要: The article provides information approval of Darzalex (Daratumumab), first monoclonal antibody therapy for treatment of Patients with relapsed multiple myeloma, by U.S. Food and Drug Administration (FDA).年份: 2016 收藏 引用 批量引用 报错 分享 ...
Daratumumab is a first in-class human IgG1 monoclonal antibody that targets CD38, and has antimyeloma effects through several mechanisms. Single-agent ... ME Cian,K Janusz,O Michael - 《Biologics Targets & Therapy》 被引量: 2发表: 2017年 Novel and Expanded Oncology Drug Approvals of 2016 ...